Incorrect Dosing Information Prompts Recall of Robaxin 750mg Tablets

This article originally appeared here.
Share this content:

Endo Pharmaceuticals has issued a recall of 2 lots of Robaxin (methocarbamol ) 750mg Tablets due to incorrect dosing information presented on the label. Rather than displaying the correct daily maintenance dosage of 2 tablets 3 times daily, the products included in the recall incorrectly state the dosing information as 2 to 4 tablets 4 times daily.

The recall involves two lots of Robaxin 750mg, 100 count bottles:

  • Lot# 216702P1 with expiration date of September 2020
  • Lot# 220409P1 with expiration date of January 2021

Robaxin is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Patients who follow the incorrect dosing directions may experience significant drowsiness or dizziness and could potentially experience serious side effects related to overdose (ie, seizures, coma, death). 

At this time, Endo has not received any reports of adverse events related to this recall. Healthcare providers are urged to report any adverse events to the Food and Drug Administration's MedWatch program.

Follow @ClinicalPainAdv

For more information call (866) 391-0620 or visit Endo.com.

You must be a registered member of Clinical Pain Advisor to post a comment.